Trupanion (TRUP) Just Gave Investors A Bigger Question

Trupanion (TRUP) is back in focus after reporting quarterly revenue of $392.9 million, an increase of 11.1% year on year, with results ahead of analyst expectations on both earnings and book value per share.

Investors have started to reprice Trupanion after the earnings beat, with the share price at $26.32 and a 90-day share price return of 11.67%, even though the 1-year total shareholder return is down 40.81%. This points to improving short-term momentum against a weak longer record.

Scan how Trupanion's earnings beat compares with other insurance players by checking the hand picked 11 resilient stocks with low risk scores that combine resilient balance sheets with controlled risk profiles.

After Trupanion’s sharp bounce over the past quarter but steep slide over the past year, the real tension is timing. Does buying after this earnings jolt make sense, or does patience for a cheaper entry look wiser as the valuation stacks up next?

Most Popular Narrative: 23% Undervalued

Against Trupanion's last close at $26.32, the most followed valuation storyline points to a fair value of $34.25. This leaves a sizeable gap that hinges on execution and margin discipline rather than another quick trading swing.

Improved underwriting discipline, focus on higher lifetime value pets, and optimization of acquisition channels are driving higher-quality book growth and supporting strong free cash flow, setting up for scalable and more profitable expansion in coming years.

See why 6 investors see Trupanion as 23% undervalued.

Result: Fair Value of $34.25 (UNDERVALUED)

Still, the bullish Trupanion narrative leans heavily on price increases over subscriber gains, as well as on rivals not accelerating ahead. Both of these factors could quickly weaken that 23% undervaluation story.

Find out about the key risks to this Trupanion narrative.

Another View: Trupanion Looks Expensive On Earnings

The first storyline paints Trupanion as 23% undervalued at $26.32 versus a $34.25 fair value. A simple earnings lens tells a very different story. The stock trades on a P/E of 49.7x, while the fair ratio is 14.4x and the US Insurance industry average is 11.4x.

That gap is wide. It implies investors today are paying more than 3x the P/E the fair ratio points to and over 4x the peer average, even though Trupanion earns a 5.7% return on equity and analysts expect earnings to grow 10.4% a year, slower than the broader US market. Is that premium a sensible way to price the pet insurance story, or is it a lot of optimism bundled into one ticker?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals around Trupanion can tempt you to lean on someone else's view, but the real edge comes from testing the numbers yourself and weighing the optimism baked into its 1 or more identified rewards, then grounding your stance in the 3 key rewards.

Looking for more investment ideas beyond Trupanion?

If Trupanion has sharpened your focus on valuation and risk, do not stop here. Fresh ideas often come from comparing very different businesses side by side.

• Target resilient balance sheets and steady fundamentals by scanning the list of solid balance sheet and fundamentals (22 results), which can help you pressure test your current holdings.
• Hunt for potential mispricing by reviewing the 34 high quality undervalued stocks, which combine earnings power with quality metrics many investors overlook.
• Spot less crowded stories by checking the 16 high quality undiscovered gems, which may not yet be front and center on most watchlists.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com